PE20100449A1 - Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas - Google Patents

Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas

Info

Publication number
PE20100449A1
PE20100449A1 PE2010000020A PE2010000020A PE20100449A1 PE 20100449 A1 PE20100449 A1 PE 20100449A1 PE 2010000020 A PE2010000020 A PE 2010000020A PE 2010000020 A PE2010000020 A PE 2010000020A PE 20100449 A1 PE20100449 A1 PE 20100449A1
Authority
PE
Peru
Prior art keywords
dysplasia
metaplasia
stains
detection
proliferative diseases
Prior art date
Application number
PE2010000020A
Other languages
English (en)
Inventor
Kai Licha
Michael Schirner
Martin Pessel
Malte Bahner
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100449(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20100449A1 publication Critical patent/PE20100449A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE CIANINA SF64, DE FORMULA (I) EN UNA CANTIDAD QUE PERMITE DETECTAR UNA ENFERMEDAD PROLIFERATIVA, CON UNA LESION PROLIFERATIVA DE 7mm DE DIAMETRO. DICHA CANTIDAD SE ADMINISTRA ENTRE 0.001 Y 0.5 mg/Kg DE PESO CORPORAL POR CADA APLICACION DE DIAGNOSTICO. REFIERE TAMBIEN QUE LA LESION PROLIFERATIVA ES: A) UNA PRECANCEROSIS TALES COMO QUERATOSIS ACTINICA, CUERNO CUTANEO, QUERATOSIS ACTINICA, ENTRE OTROS; B) UNA METAPLASIA TALES COMO UNA METAPLASIA MIELOIDE ANGIOGENICA, METAPLASIA APOCRINA, METAPLASIA ATIPICA, ENTRE OTROS; C) UNA DISPLASIA, TALES COMO DISPLASIA ECTODERMICA ANHIDROTICA, DISPLASIA ANTEROFACIAL, DISPLASIA TORACICA ASFIXIANTE; D) ENFERMEDAD OFTALMICA TALES COMO TRACOMA, RETINOPATIA DEL PREMATURO, GLAUCOMA NEOVASCULAR, ENTRE OTROS
PE2010000020A 2005-01-07 2006-01-05 Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas PE20100449A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05000276A EP1679082A1 (en) 2005-01-07 2005-01-07 Use of cyanine dyes for the diagnosis of proliferative diseases

Publications (1)

Publication Number Publication Date
PE20100449A1 true PE20100449A1 (es) 2010-07-25

Family

ID=34933224

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2010000020A PE20100449A1 (es) 2005-01-07 2006-01-05 Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas
PE2006000039A PE20060872A1 (es) 2005-01-07 2006-01-05 Colorantes de cianina en el diagnostico de enfermedades proliferativas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2006000039A PE20060872A1 (es) 2005-01-07 2006-01-05 Colorantes de cianina en el diagnostico de enfermedades proliferativas

Country Status (23)

Country Link
EP (2) EP1679082A1 (es)
JP (1) JP5578765B2 (es)
KR (1) KR20070092270A (es)
CN (1) CN101128218A (es)
AR (1) AR052190A1 (es)
AU (1) AU2006204496A1 (es)
BR (1) BRPI0606411A2 (es)
CA (1) CA2594390C (es)
CR (1) CR9232A (es)
DO (1) DOP2006000005A (es)
GT (1) GT200600001A (es)
IL (1) IL182499A0 (es)
MX (1) MX2007008300A (es)
NO (1) NO20074036L (es)
NZ (1) NZ554917A (es)
PA (1) PA8659101A1 (es)
PE (2) PE20100449A1 (es)
RU (1) RU2007129919A (es)
TW (1) TW200635612A (es)
UA (1) UA89976C2 (es)
UY (1) UY29323A1 (es)
WO (1) WO2006072580A1 (es)
ZA (1) ZA200706533B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816475A1 (en) * 2004-07-22 2007-08-08 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
EP1745739A3 (en) * 2005-07-14 2009-04-22 Bundesrepublik Deutschland, vertr. d.d. Bundes- ministerium f. Wirtschaft- und Technologie, dieses vertr. d.d. Präs. d. Phys.-Techn. Bundesanstalt Optical imaging of rheumatoid arthritis
CA2681790A1 (en) * 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Composition of labeled and non-labeled monoclonal antibodies
US20110262354A1 (en) 2007-07-13 2011-10-27 Emory University Cyanine-containing compounds for cancer imaging and treatment
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
WO2009152440A1 (en) * 2008-06-13 2009-12-17 Cedars-Sinai Medical Center Small molecule ligand-drug conjugates for targeted cancer therapy
GB0814960D0 (en) * 2008-08-15 2008-09-24 Ge Healthcare As Method for detecting dysplasia
EP2451487A1 (en) 2009-07-09 2012-05-16 F. Hoffmann-La Roche AG In vivi tumor vasculature imaging
SG177763A1 (en) 2009-07-28 2012-03-29 Hoffmann La Roche Non-invasive in vivo optical imaging method
JP2011046662A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
JP2011046663A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
US8401618B2 (en) 2009-08-28 2013-03-19 Visen Medical, Inc. Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique
US8401619B2 (en) 2009-09-22 2013-03-19 Visen Medical, Inc. Systems and methods for virtual index-matching of diffusive media
BR112012028006A2 (pt) 2010-05-07 2016-08-02 Hoffmann La Roche método de imuno-histoquímica (ihq), uso de um domínio de ligação, kit e domínio de ligação terapeuticamente ativo
JP6100704B2 (ja) 2011-03-07 2017-03-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 治療用抗体についてのインビボ試験の手段および方法
EP2683413A1 (en) 2011-03-07 2014-01-15 F.Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
KR101373108B1 (ko) 2012-01-20 2014-03-27 이화여자대학교 산학협력단 폴리메틴 체인에 메조-반응작용기를 갖는 신규한 시아닌 유도체 및 이의 제조방법
CN102608051B (zh) * 2012-02-21 2015-04-08 中国科学院化学研究所 用于诊断白血病的试剂盒
CN102703569B (zh) * 2012-05-24 2014-04-09 中国科学院化学研究所 菁染料的新用途
CN102706787B (zh) * 2012-05-24 2015-04-08 中国科学院化学研究所 菁染料的新用途
US10743768B2 (en) 2012-10-15 2020-08-18 Visen Medical, Inc. Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources
WO2014065439A1 (en) * 2012-10-26 2014-05-01 Canon Kabushiki Kaisha Cancer cell inhibitory drug and cancer stem-cell detection probe
US20150367004A1 (en) * 2012-12-10 2015-12-24 Molecular Targeting Technologies, Inc. Compositions and methods of diagnosing ocular diseases
CA2935690A1 (en) 2013-12-31 2015-07-09 Memorial Sloan Kettering Cancer Center Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real-time
RU2565645C1 (ru) * 2014-09-05 2015-10-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ рентгендиагностики глубины инвазии рецидива рака вульвы в мягкие ткани
CA2970719C (en) 2014-12-15 2023-08-01 Memorial Sloan Kettering Cancer Center Cyclic peptides with enhanced nerve-binding selectivity, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging
AU2016374246A1 (en) 2015-12-15 2018-06-28 Cornell University Imaging systems and methods for tissue differentiation, e.g., for intraoperative visualization
AU2017368005A1 (en) 2016-11-30 2019-06-20 Cornell University Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
CA3095410A1 (en) 2018-03-30 2019-10-03 Perkinelmer Health Sciences, Inc. Systems and methods for 3d reconstruction of anatomical organs and inclusions using short-wave infrared (swir) projection tomography
EP4015004A1 (en) 2020-12-18 2022-06-22 Phi Pharma SA Proteoglycan specific branched peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
JP2006513293A (ja) * 2003-01-24 2006-04-20 シエーリング アクチエンゲゼルシャフト 親水性チオール−反応性シアニン色素及び蛍光診断のための生物分子との接合体
EP1816475A1 (en) * 2004-07-22 2007-08-08 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases

Also Published As

Publication number Publication date
TW200635612A (en) 2006-10-16
CN101128218A (zh) 2008-02-20
UY29323A1 (es) 2006-10-02
IL182499A0 (en) 2007-09-20
PE20060872A1 (es) 2006-10-01
JP5578765B2 (ja) 2014-08-27
WO2006072580A1 (en) 2006-07-13
NZ554917A (en) 2010-01-29
NO20074036L (no) 2007-08-03
AU2006204496A1 (en) 2006-07-13
MX2007008300A (es) 2007-09-07
ZA200706533B (en) 2009-07-29
KR20070092270A (ko) 2007-09-12
CA2594390A1 (en) 2006-07-13
AR052190A1 (es) 2007-03-07
RU2007129919A (ru) 2009-02-20
BRPI0606411A2 (pt) 2009-06-23
DOP2006000005A (es) 2006-07-15
CR9232A (es) 2007-11-23
GT200600001A (es) 2006-08-22
EP1679082A1 (en) 2006-07-12
EP1833513A1 (en) 2007-09-19
PA8659101A1 (es) 2006-09-08
JP2008526802A (ja) 2008-07-24
UA89976C2 (ru) 2010-03-25
EP1833513B1 (en) 2013-03-06
CA2594390C (en) 2013-10-22

Similar Documents

Publication Publication Date Title
PE20100449A1 (es) Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
AR076949A1 (es) Derivados de 1h-imidazo-(4,5-c)-quinolinona
CR9748A (es) Derivados de xantina como agonistas selectivos de hm74a
BRPI0608853B8 (pt) composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
BRPI0512209A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens de um corpo humano ou de animal por formação de imagem óptica, e de monitoração do efeito de tratamento de um corpo humano ou de animal com uma droga para combater uma condição associada com angiogênese
EA200801698A1 (ru) Лекарственные композиции для применения в вагине
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
CR20120040A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades
GT200500309A (es) Derivados de sulfonilbencilimidazol
UY29245A1 (es) Combinaciones medicas
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
UY29244A1 (es) Combinaciones medicas
PE20100742A1 (es) Nuevos procedimientos y formulaciones
AR079706A1 (es) Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso
AR074778A1 (es) Composicion farmaceutica, con anticuerpo monoclonal humano anti - igf-ir.
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
ECSP067044A (es) Compuestos para el tratamiento de trastornos inflamatorios
EA200300507A1 (ru) Радиофармацевтические агенты для диагностики болезни альцгеймера
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
ECSP10010247A (es) Derivados heterocíclicos
PE20020173A1 (es) Uso de uno o mas antagonistas de aldosterona para el tratamiento o profilaxis de enfermedades mediadas por aldosterona
AR047438A1 (es) Sal amina de derivado de carboestirilo
PE20190608A1 (es) Composicion farmaceutica que comprende antagonista de receptor mineralocorticoide y su uso

Legal Events

Date Code Title Description
FD Application declared void or lapsed